• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MS4A3 通过 THAP1/EGFR 通路促进肺癌的化疗敏感性。

MS4A3 Promotes the Chemosensitivity of Lung Cancer via THAP1/EGFR Pathways.

机构信息

The Traditional of Inner Mongolia Medical University Affiliated Hospital.

出版信息

Crit Rev Eukaryot Gene Expr. 2024;34(8):1-11. doi: 10.1615/CritRevEukaryotGeneExpr.2024053662.

DOI:10.1615/CritRevEukaryotGeneExpr.2024053662
PMID:39180203
Abstract

MS4A3 functions as a tumor suppressor in multiple cancer types. However, the roles of MS4A3 in lung cancer are still unknown. Therefore, this study aims to investigate the potentials of MS4A3 in lung cancer. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was carried out to determine mRNA expression. CCK-8 and colony formation assay are conducted to determine cell proliferation. Tube formation assay is performed to determine angiogenesis. Flow cytometry is used to determine cell apoptosis. JASPAR is used to analyze the binding motif of THAP1. Luciferase and ChIP assay are conducted to verify whether MS4A3 can interact with THAP1 to transcriptionally inactivate EGFR. The results showed that MS4A3 is downregulated in non-small-cell lung cancer (NSCLC) patients, which predicts poor clinical outcomes of NSCLC patients. Overexpressed MS4A3 enhances the chemosensitivity of NSCLC cells to osimertinib, whereas MS4A3 knockdown exerts the opposite effects. MS4A3 suppresses the proliferation and angiogenesis and promotes the apoptosis of NSCLC cells. Moreover, MS4A3 upregulates apoptosis-related THAP1 to inactivate EGFR. However, THAP1 knockdown attenuates the effects of MS4A3 and promotes the malignant behavior of NSCLC cells. In conclusion, MS4A3 functions as an anti-tumor gene in NSCLC. MS4A3/THAP1/EGFR signaling enhances the chemosensitivity of lung cancer to EGFR tyrosine kinase inhibitor (TKI).

摘要

MS4A3 在多种癌症类型中作为肿瘤抑制因子发挥作用。然而,MS4A3 在肺癌中的作用尚不清楚。因此,本研究旨在探讨 MS4A3 在肺癌中的潜力。采用逆转录定量聚合酶链反应(RT-qPCR)测定 mRNA 表达。CCK-8 和集落形成实验用于检测细胞增殖。管形成实验用于检测血管生成。流式细胞术用于检测细胞凋亡。JASPAR 用于分析 THAP1 的结合基序。荧光素酶和 ChIP 实验用于验证 MS4A3 是否可以与 THAP1 相互作用以转录失活 EGFR。结果表明,MS4A3 在非小细胞肺癌(NSCLC)患者中下调,这预示着 NSCLC 患者的临床预后不良。过表达 MS4A3 增强了 NSCLC 细胞对奥希替尼的化疗敏感性,而 MS4A3 敲低则产生相反的效果。MS4A3 抑制 NSCLC 细胞的增殖和血管生成,促进其凋亡。此外,MS4A3 上调与凋亡相关的 THAP1 以失活 EGFR。然而,THAP1 敲低减弱了 MS4A3 的作用,并促进了 NSCLC 细胞的恶性行为。总之,MS4A3 在 NSCLC 中作为一种抑癌基因发挥作用。MS4A3/THAP1/EGFR 信号增强了肺癌对 EGFR 酪氨酸激酶抑制剂(TKI)的化疗敏感性。

相似文献

1
MS4A3 Promotes the Chemosensitivity of Lung Cancer via THAP1/EGFR Pathways.MS4A3 通过 THAP1/EGFR 通路促进肺癌的化疗敏感性。
Crit Rev Eukaryot Gene Expr. 2024;34(8):1-11. doi: 10.1615/CritRevEukaryotGeneExpr.2024053662.
2
AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.AXIN1/MYC 轴介导 EGFR 突变型非小细胞肺癌细胞对奥希替尼的耐药性。
Tohoku J Exp Med. 2024 May 1;262(4):269-276. doi: 10.1620/tjem.2024.J002. Epub 2024 Jan 18.
3
PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.PIM1 激酶通过调节 EGFR 突变型非小细胞肺癌中的 GSK3β 信号通路促进 EMT 相关的奥希替尼耐药。
Cell Death Dis. 2024 Sep 3;15(9):644. doi: 10.1038/s41419-024-07039-0.
4
circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).circ_PPAPDC1A 通过海绵吸附 miR-30a-3p/IGF1R 通路促进非小细胞肺癌(NSCLC)对奥希替尼的耐药性。
Mol Cancer. 2024 May 7;23(1):91. doi: 10.1186/s12943-024-01998-w.
5
ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.ID1 通过上皮-间充质转化介导 EGFR T790M 阳性非小细胞肺癌对奥希替尼的耐药性。
BMC Pulm Med. 2021 May 15;21(1):163. doi: 10.1186/s12890-021-01540-4.
6
Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.二氢青蒿素克服 EGFR 突变型非小细胞肺癌对奥希替尼的耐药性。
Pharmacol Res. 2021 Aug;170:105701. doi: 10.1016/j.phrs.2021.105701. Epub 2021 Jun 1.
7
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.胰岛素样生长因子-1 受体的激活赋予 EGFR T790M 突变的非小细胞肺癌对奥希替尼的获得性耐药。
Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.
8
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer.ONO-7475,一种新型的 AXL 抑制剂,抑制了 - 突变非小细胞肺癌对初始 EGFR-TKI 治疗的适应性耐药。
Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17.
9
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.支链氨基酸转氨酶 1 通过表观遗传糖酵解激活赋予 EGFR-TKI 耐药性。
Signal Transduct Target Ther. 2024 Aug 15;9(1):216. doi: 10.1038/s41392-024-01928-8.
10
MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.MUSASHI-2 赋予肺腺癌对第三代 EGFR 酪氨酸激酶抑制剂奥希替尼的耐药性。
Cancer Sci. 2021 Sep;112(9):3810-3821. doi: 10.1111/cas.15036. Epub 2021 Jul 13.

引用本文的文献

1
Circular RNA hsa_circ_103089 modulates metabolic glycolysis and influences migration, invasion, and cisplatin sensitivity in non-small cell lung cancer cells via the miR-876-5p/EGFR axis.环状RNA hsa_circ_103089通过miR-876-5p/表皮生长因子受体轴调节非小细胞肺癌细胞的糖酵解代谢,并影响其迁移、侵袭及顺铂敏感性。
Am J Cancer Res. 2025 May 25;15(5):2353-2374. doi: 10.62347/PXHT9575. eCollection 2025.
2
Effects of ER-phagy regulatory genes on the microenvironment of hepatocellular carcinoma: a comprehensive analysis.内质网自噬调节基因对肝细胞癌微环境的影响:一项综合分析
Discov Oncol. 2025 May 17;16(1):795. doi: 10.1007/s12672-025-02649-2.